A Clinical Study of Semaglutide Nasal Spray in Overweight or Obese Adults

NCT07465965 · Recruiting

Last updated 2026-05-28

This clinical trial is testing a semaglutide nasal spray to see how it is absorbed in the body of adults who are overweight or obese.

Status Recruiting Currently enrolling participants.

Phase Phase 1 Checks safety and dosing in a small group.

Type Interventional (clinical trial)

Design Randomized, quadruple-blind treatment study

Participants 60 people Planned (estimated).

Who can join Ages 18–65 · all sexes

Timeline Started 2026-03 · est. completion 2026-08

Where 1 site · United States

What this study is testing ClinicalTrials.gov NCT07465965 ↗

Description as written by the study sponsor.

The specific aim of this study is to examine the Safety, Tolerability and Pharmacokinetic of Semaglutide Nasal Spray compared with placebo and positive control in Adult Overweight or Obese Participants.

Treatments tested

Semaglutide Nasal Spray Drug

WL1006
Placebo Drug

WL1006
Semaglutide Injection Drug

Wegovy®

Main thing measured	Maximum Plasma Concentration (Cmax)
Sponsor	Shanghai World Leader Pharmaceutical Co., Ltd.
Conditions studied	Overweight, Obesity
GLP-1 drugs	semaglutide

Full protocol, eligibility, and contacts on ClinicalTrials.gov NCT07465965 ↗